Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
9.04
-0.52 (-5.44%)
Mar 31, 2025, 1:26 PM EDT - Market open
Entrada Therapeutics Employees
Entrada Therapeutics had 183 employees as of December 31, 2024. The number of employees increased by 24 or 15.09% compared to the previous year.
Employees
183
Change (1Y)
24
Growth (1Y)
15.09%
Revenue / Employee
$1,151,814
Profits / Employee
$358,612
Market Cap
322.06M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 183 | 24 | 15.09% |
| Dec 31, 2023 | 159 | 29 | 22.31% |
| Dec 31, 2022 | 130 | 16 | 14.04% |
| Dec 31, 2021 | 114 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TRDA News
- 7 days ago - Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping - GlobeNewsWire
- 4 weeks ago - Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 5 weeks ago - Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44 - GlobeNewsWire
- 5 weeks ago - Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside - Seeking Alpha
- 2 months ago - Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy - GlobeNewsWire
- 2 months ago - Azenta Announces the Election of Dipal Doshi to its Board of Directors - PRNewsWire
- 3 months ago - Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 months ago - Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society - GlobeNewsWire